For Beneficence, Let Cloning for Research Continue

For Beneficence, Let Cloning for Research Continue Leon Kass, chairman of the president's advisory council on bioethics, claims that "cloning represents a turning point in human history. ... It thus carries with it a number of troubling consequences for children, family, and society."1 It's notable that the only "consequences" Kass discusses are those of the "troubling" variety. Conspicuously absent are the positive aspects of this turning point: possible scientific breakthroughs, the chance

Written byTed Peters
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Leon Kass, chairman of the president's advisory council on bioethics, claims that "cloning represents a turning point in human history. ... It thus carries with it a number of troubling consequences for children, family, and society."1 It's notable that the only "consequences" Kass discusses are those of the "troubling" variety. Conspicuously absent are the positive aspects of this turning point: possible scientific breakthroughs, the chance for medical research to alleviate suffering.

The consideration of potential harms is crucial. But proscriptions of harm must be balanced by prescriptions for healing. One need not disagree with their conclusions to recognize that the majority's ethical reflection is guided almost exclusively by nonmaleficence, a careful guarding against harm. By contrast, concern for stewarding resources to improve human well-being, or beneficence, is demoted to a secondary consideration.

A 10-member majority of the Kass council opposes cloning-for-biomedical-research, effectively ruling out embryonic stem cell research. Their argument ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies